Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a company dedicated to developing and commercializing treatments for rare diseases, will actively participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York City. Members of Eton's executive leadership team are set to host one-on-one meetings, offering institutional investors a valuable opportunity to discuss the company's growth strategies and product pipeline. Interested parties can arrange these meetings through their Craig-Hallum institutional sales representatives.

Eton Pharmaceuticals is recognized for its innovative approach within the pharmaceutical industry, currently offering eight commercial products tailored for rare diseases. These products encompass KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone, reflecting the company's commitment to addressing unmet medical needs in niche markets.

In addition to its marketed products, Eton is advancing five late-stage development candidates, including ET-600, Amglidia®, ET-700, ET-800, and the ZENEO® hydrocortisone autoinjector. This diversified product pipeline showcases the company's innovative efforts to enhance treatment options for patients suffering from rare disorders.

Eton's focus on rare diseases positions it strategically in the pharmaceutical landscape, as these conditions often lack sufficient treatment options, providing Eton with a unique market opportunity. Interested investors and stakeholders can learn more about Eton Pharmaceuticals and its initiatives by visiting their website at www.etonpharma.com.

For further inquiries, Lisa M. Wilson from In-Site Communications, Inc. is available to provide additional information about Eton's participation in the conference and its corporate strategies.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative player in the rare disease pharmaceutical sector, will be participating in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York. This event presents a strategic opportunity for investors to gain insights into the company’s operational and financial trajectory directly from its executive leadership.

Eton boasts a diversified portfolio with eight commercially available rare disease treatments and five additional candidates in late-stage development, emphasizing its robust position within a niche but essential market. Investors should pay particular attention to its late-stage pipeline products, including ET-600 and the ZENEO® hydrocortisone autoinjector, as their upcoming data and potential commercialization could significantly drive future revenue growth.

The context of Eton’s participation at this conference is particularly important given the ongoing trends and challenges in the pharmaceutical sector, such as pricing pressures and regulatory hurdles. However, Eton appears to be well-positioned to tackle these issues with its focused portfolio on rare diseases—an area often characterized by less competition and favorable market dynamics.

Moreover, investors may find value in scheduling one-on-one meetings with Eton’s executives during the conference. These meetings present a prime opportunity for personalized insights into the company's strategic direction, market positioning, and product pipeline, which could influence investment decisions.

In light of Eton’s showcasing at the Craig-Hallum conference, market participants are encouraged to monitor its stock closely, especially for announcements related to clinical trial outcomes or partnerships that could catalyze its growth. As always, potential investors should conduct due diligence and consider Eton’s risk-reward profile in the context of their investment strategy.